Bristol-Myers Squibb Plans to Build Biologics Facility in the U.S.
Posted on: Wednesday, 8 March 2006, 09:01 CST
NEW YORK, March 8 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company said today that it will build its new biologics facility in the United States. At its regularly scheduled meeting on March 7, the company's Board of Directors approved a capital expenditure in the amount of $660 million for the construction of a large-scale multi-product bulk biologics manufacturing facility. The facility will be modular in design in order to accommodate future expansion.
Anthony C. Hooper, President, U.S. Pharmaceuticals, will discuss the company's biologics plans and other recent company developments at the Cowen & Co. 26th Annual Health Care Conference in Boston today. The conference will be webcast at http://www.bms.com/ at 1:40 p.m. ET. Mr. Hooper will update investors on the recent launch of ORENCIA(R) (abatacept), the company's first internally developed biologic. ORENCIA was approved by the U.S. Food and Drug Administration (FDA) in December 2005 for the treatment of rheumatoid arthritis and has been available to patients since mid-February. Mr. Hooper will also update investors on ERBITUX(R), which it co-markets with ImClone Systems Incorporated. On March 1, ERBITUX received FDA approval for use in the treatment of squamous cell carcinoma of the head and neck. He will also discuss the recent approval of EMSAM(R) (selegiline transdermal system), a transdermal patch that was approved by the FDA on Feb. 27 for the treatment of major depressive disorder in adults.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Bristol-Myers Squibb Company
CONTACT: Media: Tony Plohoros, Communications, +1-212-546-4379,tony.plohoros@bms.com, or Investors: John Elicker, Investor Relations,+1-212-546-3775, john.elicker@bms.com, or Blaine Davis, Investor Relations,+1-212-546-4631, blaine.davis@bms.com, all of Bristol-Myers Squibb Company
Web site: http://www.bms.com/
Source: PRNewswire-FirstCall
Related Articles
- Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma
- Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (Saxagliptin) for the Treatment of Type 2 Diabetes
- FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Ixabepilone
- Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds
- Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Discover and Develop Novel Oncology Compounds
- Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment
- FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Dasatinib
- Bristol-Myers Squibb Submits New Drug Application for Dasatinib
- ImClone Systems Incorporated and Bristol-Myers Squibb File Supplemental Biologics License Application for ERBITUX(R) for Treatment of Head and Neck Cancer
- Bristol-Myers Squibb Announces Intent to Pursue FDA Approval of Pravachol(R) (Pravastatin Sodium) As an OTC Cholesterol-Lowering Therapy
 |
 |
User Comments (0)
RSS Feeds